While MDM4 alterations were absent in FGFR3-TACC3 fusion-positive gliomas, there is an association with a higher prevalence of MDM2 alterations and CDK4 amplifications, which can be found in 19% and 10%, respectively, of fusion-positive glioblastoma [84]. This evidence concerns the gene FGFR3 and central nervous system cancer.